
Uncertainty in an era of transformative therapy for hemophilia | Virtual Summit 2020
In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

In this session from the WFH 2020 World Summit, Glenn Pierce will examine the evolution of gene therapy while addressing

This document is also available in: English, French, Spanish This is not an official WFH translation. This resource has been

Despite significant paradigm shifts in the medical management of hemophilia A with inhibitors and the expanding use of novel non-factor

This module was presented by Susan Cutter at the Virtual Workshop for Psychosocial Professionals in Central and South America on

In this session from the WFH 2020 Virtual Summit, Steve Kitchen, Emmanuel Favaloro, Robert Gosselin and Geoffrey Kershaw discuss: How

In this session from the WFH 2020 Virtual Summit, Steve Kitchen, Stefen Tiefenbacher, Anna Lowe and Annette Bowyer discuss: Gene